candesartan

(redirected from Blopress)
Also found in: Dictionary, Wikipedia.

candesartan

 [kan″dĕ-sahr´tan]
an angiotensin II receptor antagonist, used in the treatment of hypertension; administered orally as candesartan cilexetil.

candesartan

/can·de·sar·tan/ (kan″dĕ-sahr´tan) an angiotensin II receptor antagonist, used in the treatment of hypertension; administered orally as c. cilexetil.

candesartan

an antihypertensive in the angiotensin II receptor antagonist class.
indications It is used to treat hypertension, either alone or in combination with other drugs.
contraindications Known hypersensitivity to this drug prohibits its use.
adverse effects Angioedema is a potentially life-threatening side effect. Dizziness, diarrhea, cough, and upper respiratory infection are common side effects. Other side effects include fatigue, headache, nausea, arthralgia, and pain.

candesartan

An ANGIOTENSIN II antagonist drug used in the treatment of high blood pressure (HYPERTENSION). A brand name is Amias.
References in periodicals archive ?
This launch will also enable Aska to provide healthcare professionals and patients with an AG that contains identical active pharmaceutical ingredients, additives, and production method as Blopress.
Aska and Takeda will strengthen their contributions to the treatment of hypertension through Blopress AG and will continue to provide pharmaceutical products to meet various medical needs.
Table 27: Blopress Comp: sales forecast ($m), 2008-14 83
Actos, Lupron, Blopress and Takepron have provided the sales to enable 16 years of consistent revenue growth and pharmaceutical sales in excess of Y=1 trillion.
Products Mentioned: Blopress Diovan Epogin Gaster Leuplin Lipitor Mevalotin Mohrus Hisamitsu Norvasc Nu Lotan Companies Mentioned: -Takeda Yakuhin Kog -Pfizer -Chugai Seiyaku -Astellas Seiyaku -Novartis Pharma -Eisai -Daiichi Seiyaku -Sankyo -Glaxosmithkline -Dainippon Sumitomo -Otsuka Seiyaku -Mitsubishi Pharma -Astrazeneca -Banyu Seiyaku -Shionogi Seiyaku -Tanabe Seiyaku -Ono Yakuhin Kogyo -Nippon Boehringer -Sanofi-Aventis -Taiho Yakuhin Kogy -Kyowa Hakko Kogyo -Abbott Japan -Santen Seiyaku -Hisamitsu Seiyaku -Bayer Yakuhin -Taisho Toyama Iyak -Eli Lilly Japan -Schering-Plough -Meiji Seika -Tsumura -Kowa Soyaku -Novo Nordisk Pharm -Bristol-Myers -Mochida Seiyaku -Kaken Seiyaku
Takeda's pipeline is largely dominated by new indications/ formulations for its core products Actos, Takepron, Blopress and Lupron.
Major Products Forecast to 2010 Actos (Diabetes) Basen (Diabetes) Takepron (Gastrointestinal) Blopress (Cardiovascular) Lupron (Cardiovascular) Isovorin (Gastrointestinal) Benet (Musculoskeletal) Seltouch (Musculoskeletal)
Understand how the blockbusters Actos and Blopress will drive company sales growth in the near-term but face competitive threats in the medium-term
The current operations in Ireland are responsible for the production of the diabetes drug pioglitazone (trade name: Actos), the hypertensive drug candesartan (trade name: Blopress, Amias, Kenzen, etc.